Diabetes und komorbide Depression: Systematische Literaturübersicht gesundheitsökonomischer Studien

Lehnert, Thomas; Konnopka, Alexander; Riedel‐Heller, Steffi G.; König, Hans‐Helmut

doi:10.1055/s-0031-1276934

Cited by 18 publications

(8 citation statements)

References 33 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kausalität und Richtung eines Zusammenhangs zwischen beiden Erkrankungen sind ungeklärt [4]. Bei gleichzeitigem Vorliegen einer Depression bei Patienten mit Diabetes ist mit einer höheren Komplikationsrate [5], erhöhter Morbidität und Mortalität [6,7] und erhöhten Behandlungskosten [8] zu rechnen. Diabetes und Depressionen sind für sich genommen häufige Erkrankungen bei Erwachsenen in Deutschland [9 -11].…”

unclassified

Komorbidität von Diabetes mellitus und Depression in Deutschland

et al. 2014

Self Cite

View full text Add to dashboard Cite

Comorbidity of diabetes and depression was quite rare. Yet according to our results every 10(th) adult with diagnosed diabetes gets a depression diagnosis and every 9(th) adult with diagnosed depression has known diabetes. Underestimation for men and older adults due to diagnostic bias is possible. The combination of diabetes and depression is relevant for medical care because of its health burden.

show abstract

unclassified

Komorbidität von Diabetes mellitus und Depression in Deutschland

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that somatic patients with comorbid depressive symptoms have a reduced adherence to medical therapy [49–52] and that depression can interfere with treatment and recovery from AE. This may contribute to the fact that patients who have both a somatic and a mental disease show higher levels of symptom burden [53], a higher mortality [4–6], and produce increased health care costs [9]; the latter aspect is mainly attributable to medical, and not to psychosocial care [10]. Despite these facts, there are no studies focusing on depression in AE patients and the role of depression in the development and progression of AE.…”

Section: Discussionmentioning

confidence: 99%

“…Compared to persons who either have a physical or mental health problem, patients who present both a somatic illness and a psychological comorbidity show dramatically reduced outcomes in all important dimensions of health: they have higher mortality rates [4–7] as well as higher levels of symptom burden and impairment in any medical disorder index [8]. In addition, health care costs are significantly higher in patients with both chronic conditions and comorbid mental disorders [9], although the increased costs are mainly due to medical, and not psychosocial care [10].…”

Section: Introductionmentioning

confidence: 99%

Psychological burden and resilience factors in patients with Alveolar Echinococcosis – A cross-sectional study

et al. 2019

View full text Add to dashboard Cite

BackgroundAlveolar echinococcosis (AE) is a parasitic zoonosis resembling malignancy due to its clinically silent infiltrative growth, predominately in the liver. The comorbid psychological burden and fear of disease progression in AE patients have hardly been examined to date. The aim of this study was to evaluate depression, anxiety, quality of life, and fear of disease progression in AE patients.Methodology/Principal findingsIn a cross-sectional study, n = 57 AE patients were invited to report on depression (PHQ-9), anxiety (GAD-7), somatic symptom load (SSS 8), trauma symptoms (PTSS-10), quality of life (SF-12) and on fear of disease progression (FoP-Q-SF) using validated psychometric instruments. Furthermore, attachment style was assessed (RQ-2). N = 47 patients completed the questionnaires (response rate 82.5%). Depression, anxiety, and somatic symptom load were above norm sample means, while physical quality of life was below norm sample means. Existing traumatic symptoms were comparable to those in cancer patients, while fear of disease progression even exceeded cancer patient scores. Patients with a secure attachment style showed less pronounced psychological burden than patients with other attachment styles. Adequate, guideline-based depression and anxiety treatment was very rarely installed.Conclusion/SignificanceThe present study revealed remarkable levels of psychological burden in AE patients. In our study sample, we discovered high depression and anxiety levels, a significant reduction of physical quality of life, and fear of disease progression. These results show how important it is for AE patients to be thoroughly assessed with regard to psychological symptoms and mental disorders so that those in need can receive sufficient psychosocial support and treatment according to official guidelines.

show abstract

“…Owing to rising life expectancy, the prevalence of dementia is estimated to increase to 3 million cases in Germany by 2050 [ 6 ]. Cognitive impairment causes high economic and societal burden due to the high costs of care, especially for institutionalization [ 7 – 10 ].…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness of a non-pharmacological treatment vs. “care as usual” in day care centers for community-dwelling older people with cognitive impairment: results from the German randomized controlled DeTaMAKS-trial

et al. 2020

View full text Add to dashboard Cite

Background Cognitive impairment in older adults causes a high economic and societal burden. This study assesses the costeffectiveness of the multicomponent, non-pharmacological MAKS treatment vs. "care as usual" in German day care centers (DCCs) for community-dwelling people with mild cognitive impairment (MCI) or mild to moderate dementia over 6 months. Methods The analysis was conducted from the societal perspective alongside the cluster-randomized controlled, multicenter, prospective DeTaMAKS-trial with waitlist group design. Outcomes were Mini-Mental Status Examination (MMSE) and Erlangen Test of Activities of Daily Living in Persons with Mild Dementia or Mild Cognitive Impairment (ETAM) of 433 individuals in 32 DCCs. Incremental differences in MMSE and ETAM were calculated via a Gaussian-distributed and incremental cost difference via a Gamma-distributed Generalized Linear Model. Cost-effectiveness was assessed via costeffectiveness planes and cost-effectiveness acceptability curves (CEAC). Results At 6 months, MMSE (adjusted mean difference = 0.92; 95% confidence interval (CI): 0.17 to 1.67; p = 0.02) and ETAM (adjusted mean difference = 1.00; CI: 0.14 to 1.85; p = 0.02) were significantly better in the intervention group. The adjusted cost difference was − €938.50 (CI: − 2733.65 to 763.13; p = 0.31). Given the CEAC, MAKS was cost-effective for 78.0% of MMSE and 77.4% for ETAM without a need for additional costs to payers. Conclusions MAKS is a cost-effective treatment to stabilize the ability to perform activities of daily living and cognitive abilities of people with MCI or mild to moderate dementia in German DCCs. Thus, MAKS should be implemented in DCCs.

show abstract

Diabetes und komorbide Depression: Systematische Literaturübersicht gesundheitsökonomischer Studien

Cited by 18 publications

References 33 publications

Komorbidität von Diabetes mellitus und Depression in Deutschland

Komorbidität von Diabetes mellitus und Depression in Deutschland

Psychological burden and resilience factors in patients with Alveolar Echinococcosis – A cross-sectional study

Cost-effectiveness of a non-pharmacological treatment vs. “care as usual” in day care centers for community-dwelling older people with cognitive impairment: results from the German randomized controlled DeTaMAKS-trial

Contact Info

Product

Resources

About